Skip to main content
TipRanks
Go Ultimate75% OFF

AbCellera Biologics (8QQ) Q3 2026 Earnings Report

7 Followers

DE:8QQ Q3 2026 EPS Results

Actual EPS
-EUR 0.12
Consensus EPS
-EUR 0.16
Beat/Miss
Beat by +EUR 0.04
One Year Ago EPS
-EUR 0.17

DE:8QQ Q3 2026 Revenue Results

Actual Revenue
EUR 9.68M
Expected Revenue
EUR 7.66M
Beat/Miss
Beat by +EUR 2.02M
YoY Revenue Growth
+18.81%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/09/2026
Time
After Close
Conference Call
Monday, November 9, 2026
DE:8QQ Upcoming Earnings

AbCellera Biologics's next earnings date is estimated for February 23, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:8QQ Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 09, 2026|% Change Since:-3.58%|
Earnings Call Sentiment|Positive

The call was strongly positive, driven by ABCL635's substantial Phase II efficacy, favorable tolerability, positive clinician feedback, planned late-stage development in 2027, pipeline expansion and a strengthened liquidity position. The principal setbacks were the decision to halt ABCL575 development beyond Phase I, the expected decline in ABCL635 efficacy during the single-dose washout period, pending longer-term immunogenicity data and the company's continued net loss. Overall, the highlights significantly outweighed the lowlights.

Company Guidance

AbCellera expects to disclose additional ABCL635 data through 12 weeks and open-label extension data in early 2027, initiate late-stage development for menopause VMS in 2027, and initiate clinical trials in breast and prostate cancer treatment populations in 2027, with prostate cancer mid-stage studies expected to begin in 2027; ABCL688 and ABCL386 are expected to enter the clinic in 2027, ABCL992 perhaps in 2028, and no further guidance was given for ABCL646 and ABCL385. The company said it has over $790 million in cash and equivalents, over $100 million in available committed government funding, over $890 million in available liquidity, and sufficient liquidity to fund at least the next 3 years of pipeline investments; ABCL575 will not be pursued beyond Phase I at this time.

  • ABCL635 Delivered Strong Phase II EfficacyABCL635 produced a mean reduction of 8.8 moderate-to-severe hot flashes per day at 4 weeks versus 3.5 for placebo, for a placebo-adjusted difference of 5.3 events. This represented an 83% reduction from baseline versus 33% for placebo, or a 50% placebo-adjusted treatment difference.
  • Rapid and Clinically Meaningful Improvement in Symptom SeverityABCL635 showed significant improvement by week 1, with mean severity scores decreasing by 1.4 points versus 0.3 points for placebo at week 4. The treatment group experienced a 58% reduction in severity from baseline versus 12% for placebo, for a placebo-adjusted difference of 46%.
  • High Rates of Complete or Substantial Symptom ResolutionAt 4 weeks, 37% of ABCL635 participants experienced complete or 100% resolution of moderate-to-severe events versus 2.2% for placebo. Nearly 61% achieved at least a 90% improvement, compared with 8.7% for placebo, and 78% achieved more than a 75% reduction.
  • Efficacy Compared Favorably With Approved Small-Molecule TreatmentsThe company reported a 50% placebo-adjusted reduction in moderate-to-severe hot flash frequency, approximately twice the 20% to 25% reductions reported in Phase III studies of fezolinetant and elinzanetant. The improvement in severity was described as roughly 3.5 to fivefold greater than in those registrational studies, while acknowledging the limitations of cross-trial comparisons.
  • Favorable ABCL635 Safety and Tolerability ProfileThe company reported no clear gastrointestinal or liver toxicity with ABCL635. There were no serious or severe adverse events in the ABCL635 group, no diarrhea or abdominal pain, and a lower incidence of nausea than in the placebo group. Headache occurred more often with ABCL635 and fatigue was also reported more often, but the events were described as mild, with headaches generally mild and transient.
  • ABCL635 Advancing Toward Late-Stage DevelopmentAbCellera is committed to advancing ABCL635 into late-stage development in 2027 and is working through the FDA's model-informed drug development program to align on dose selection. The company remains on track to initiate late-stage studies in 2027 while continuing regulatory, key opinion leader and manufacturing discussions.
  • Expansion of ABCL635 Into Additional Cancer-Related IndicationsThe company plans to expand ABCL635 into hot flashes caused by hormone suppression associated with breast and prostate cancer treatment, with clinical trials in both populations expected to begin in 2027. Breast cancer studies are expected to resemble the OASIS-4 design, while prostate cancer studies are expected to begin as mid-stage studies.
  • New Long-Acting ABCL992 Program Entered IND-Enabling ActivitiesABCL992, a next-generation half-life-extended analog of ABCL635, entered IND-enabling activities in Q3. The company said the program is intended to provide greater convenience through an extended dosing interval and broader patient reach, while emphasizing that ABCL992 does not represent a move away from ABCL635.
  • Positive Clinician and Market Reception for ABCL635The company described the reception from clinicians at IMS in Rio and The Menopause Society meeting in San Diego as 'nothing short of incredible.' Clinicians reportedly expressed interest in when Phase III would begin and said the results appeared stronger than their experience with hormonal therapy in some comparisons.
  • ABCL575 Demonstrated Favorable Phase I ResultsIn a Phase I study of 40 healthy volunteers, ABCL575 showed comparable adverse-event rates between treatment and placebo, with about 57% of ABCL575 participants reporting at least one adverse event versus 60% on placebo. There were no serious or severe adverse events in the ABCL575 group, no findings indicative of clinically important immunosuppression, and injection-site reactions and headache were neither dose-dependent nor markedly different from placebo.
  • ABCL575 Supported Extended DosingABCL575 demonstrated approximately dose-proportional exposure and a mean half-life of approximately 65 days, ranging from 43 days in the lowest dose cohort to 79 days in the 600-milligram cohort. Exposures at clinically relevant dose levels remained above the 4 micrograms per milliliter efficacy target threshold for over 12 weeks, supporting dosing once a quarter or less frequently.
  • Pipeline Expansion and Continued Program ProgressABCL688 and ABCL386 continued through IND-enabling activities, while ABCL992, ABCL385 for an undisclosed oncology indication and ABCL646, a potential first-in-class antibody antagonist against an undisclosed ion channel target, were added to the pipeline. ABCL688 and ABCL386 are expected to enter the clinic in 2027, while ABCL992 may enter the clinic in 2028.
  • Successful Transition to a Clinical BiotechThe company stated that it had successfully brought its first two programs through early-stage clinical development and expects to transition into a late-stage clinical development company in 2027. Management also said it delivered on all stated 2026 corporate priorities.
  • Strengthened Balance Sheet and LiquidityFollowing the ABCL635 Phase II data, AbCellera completed a significantly oversubscribed $200 million capital raise. The company ended the quarter with over $790 million in cash and equivalents or marketable securities, more than $100 million in available committed government funding, and over $890 million in available liquidity when including unused secured government funding. Management said this was sufficient to fund at least the next 3 years of pipeline investments.
  • Improved Net Loss and Lower SG&A ExpensesThird-quarter revenue was over $10 million versus approximately $9 million in Q3 2025. Net loss improved to roughly $41 million from about $57 million a year earlier, while SG&A declined to approximately $14 million from $25 million, primarily due to the conclusion of intellectual property litigation and changes in teams.
  • Operating Cash Generation and Government FundingOperating activities generated $19 million in cash during the first 9 months of the year. Financing cash inflows totaled $214 million, including proceeds from the $200 million equity raise, government funding and employee stock option exercises. Year-to-date capital expenditures were approximately $8 million, offset by a similar amount in government grants received.

DE:8QQ Earnings History

DE:8QQ earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 23, 20272026 (Q4)-0.14--0.03――
Nov 09, 20262026 (Q3)-0.16-0.12-0.1731.58% (+0.05)
Aug 05, 20262026 (Q2)-0.15-0.16-0.11-50.00% (-0.05)
May 11, 20262026 (Q1)-0.16-0.13-0.146.67% (+0.01)
Feb 24, 20262025 (Q4)-0.12-0.03-0.1175.00% (+0.08)
Nov 06, 20252025 (Q3)-0.13-0.17-0.15-11.76% (-0.02)
Aug 07, 20252025 (Q2)-0.12-0.11-0.127.69% (+0.01)
May 08, 20252025 (Q1)-0.12-0.14-0.13-7.14% (-0.01)
Feb 27, 20252024 (Q4)-0.12-0.11-0.1525.00% (+0.04)
Nov 04, 20242024 (Q3)-0.11-0.15-0.09-70.00% (-0.06)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed